From Terminal to Cancer-Free: The Stage IV Stories Behind the Movement

Source note: this article draws on a recorded interview with an oncologist describing outcomes from his own cancer coaching practice, plus two previously published cases — the Joe Tippens story and a Stanford University Medical Center case series. These are individual reports and small case series, not clinical trial results. They are presented here as what they are: the human stories driving interest in these drugs, not evidence that they work.

The man who was supposed to die

Joe Tippens, from Oklahoma, was diagnosed with stage IV small cell lung cancer — one of the most aggressive cancers there is. He was given a five-year survival estimate of less than 1%. He enrolled in a clinical trial for an immune checkpoint inhibitor, a standard-of-care cancer drug. By his own account, told later on television interviews, every other patient on that trial died. He was the only one who survived.

The detail that made his story spread was what he says he did alongside the trial drug: a veterinarian friend told him about fenbendazole, a dog dewormer that had, by accident, turned up anti-cancer properties in mouse studies — cheap, safe, and not approved for use in humans. Tippens tried it. He describes his stage IV cancer as having resolved entirely, and as of the interview this article is drawn from, he was reportedly still cancer-free seven years later. It is a single, well-publicized case, and it is the origin point for what's now informally called the "Joe Tippens protocol" — the reason fenbendazole entered the cancer conversation at all.

The case series a university was allowed to publish but not endorse

Separately, Stanford University Medical Center published a case series describing three patients who became cancer-free after taking fenbendazole. All three had already failed three or four lines of standard chemotherapy and were considered terminal. The Stanford researchers monitored and analyzed the outcomes and published them — while being explicit that, because fenbendazole is not FDA-approved for this use, they were not in a position to recommend it to other doctors or patients. They published what they observed anyway, because they judged it worth the medical community's attention.

A similar pattern shows up in an unrelated corner of the literature: case reports of two patients in their 80s with lung cancer who declined chemotherapy outright and whose tumors nonetheless resolved over several months while taking CBD oil. Their oncologists, initially just monitoring them without treatment, eventually asked what they were doing differently — and once they did, the case got written up and published. The oncologist interviewed for this piece holds this up as a model for what should happen more often: an unexpected result should provoke a question, not a shrug.

What one practice has reported

The physician interviewed here runs a private cancer coaching practice — not a conventional oncology clinic — where clients bring him their diagnosis and their existing oncology plan, and he discusses the preclinical research on repurposed drugs with them. He is careful to frame this as a supplement to standard oncology care, not a replacement, and encourages patients to keep pursuing chemotherapy, radiation, and whatever else their oncologist recommends. Within that practice, he describes:

• Multiple stage IV pancreatic cancer patients he says have been declared cancer-free by their own oncologists.
• Cholangiocarcinoma and ovarian cancer patients whose tumors were shrinking despite having failed multiple lines of chemotherapy.
• A breast cancer patient whose surgery was delayed several months for scheduling reasons. She had a 7 cm tumor and imaging suggesting positive lymph nodes. By the time her surgery took place, roughly three months after starting ivermectin and mebendazole, her tumor had shrunk to under 3 cm and the lymph nodes that imaging had flagged as involved came back clear.
• A physician assistant, five cycles into chemotherapy, who added ivermectin and — for the first time — had no chemo side effects at all, playing golf the day after his infusion instead of losing three days to being knocked flat. He says the same thing happened on the cycles that followed, alongside markers that kept dropping.

He also describes radiation oncologists reacting with visible surprise when tumors shrink dramatically after only two or three radiation treatments — a response he attributes to ivermectin's reported radiosensitizing effect, invisible to a radiation oncologist who has no idea the patient is also taking it.

The trust problem underneath all of it

Here is the complication that runs through every story above: most of these patients never told their oncologist what they were doing. In his account, patients who have disclosed ivermectin or benzimidazole use to their oncologists — particularly outside the United States — have sometimes been threatened with being dropped as a patient. He describes this happening more often in Canada, the UK, and Australia than in the US, and cites one Canadian physician, referred to in the interview as Dr. Khan, who reportedly relocated his practice to Florida after years of conflict with a Canadian medical regulator over prescribing repurposed drugs. These specific claims come from the interview and have not been independently verified for this article.

The consequence, whether or not every detail holds up, is structural: if patients hide their use of these drugs, and oncologists don't ask, then the outcomes — good or bad — never get systematically recorded. No one is collecting the data that would let anyone tell, at scale, whether these stories represent a real, reproducible effect or a much smaller signal dressed up by selection: the patients who do well are the ones who tell their story; the ones who don't are rarely heard from at all.

Why a good story is not a good trial

None of this should be read as proof that ivermectin or fenbendazole treat cancer. A single patient's remission, even a remarkable one, cannot rule out that his checkpoint inhibitor did the work on its own. A case series of three Stanford patients is real and worth publishing, but three cases cannot establish a response rate, let alone rule out that some of those patients would have responded to a later line of chemotherapy anyway. And a private practice's internal case log, however consistent it sounds from the inside, is not the same as outcomes tracked against a control group by researchers with no stake in the result.

The physician interviewed here is direct about what he thinks should happen next: that researchers doing this work need to be supported, regardless of the fact that — because both drugs are off-patent — there is no pharmaceutical company or set of shareholders standing to profit from funding that research. In his framing, that is precisely why it hasn't been done, and precisely why it should be: work done for a patient's benefit rather than a corporate one still needs the human trials that, so far, this field has never received.